IDEXX Laboratories, Inc. Stock
Equities
IDXX
US45168D1046
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
483.7 USD | +1.43% | -1.84% | -12.86% |
May. 02 | BNP Paribas Adjusts Price Target on IDEXX Laboratories to $641 From $653 | MT |
May. 02 | Goldman Sachs Adjusts Price Target on IDEXX Laboratories to $600 From $675 | MT |
Financials (USD)
Sales 2024 * | 3.94B | Sales 2025 * | 4.35B | Capitalization | 39.38B |
---|---|---|---|---|---|
Net income 2024 * | 922M | Net income 2025 * | 1.04B | EV / Sales 2024 * | 10.1 x |
Net Debt 2024 * | 472M | Net Debt 2025 * | 259M | EV / Sales 2025 * | 9.12 x |
P/E ratio 2024 * |
43.1
x | P/E ratio 2025 * |
38
x | Employees | 11,000 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.19% |
Latest transcript on IDEXX Laboratories, Inc.
1 day | +1.74% | ||
1 week | -1.54% | ||
Current month | -1.54% | ||
1 month | -5.73% | ||
3 months | -15.22% | ||
6 months | +14.85% | ||
Current year | -12.59% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 12-07-31 | |
Brian McKeon
DFI | Director of Finance/CFO | 61 | 03-06-30 |
John Hart
COO | Chief Operating Officer | - | 07-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Junius
BRD | Director/Board Member | 71 | 14-03-10 |
M. Szostak
BRD | Director/Board Member | 73 | 12-07-15 |
Chairman | 61 | 16-10-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
8.32% | 1 M€ | -.--% | ||
1.59% | 0 M€ | +5.44% | - | |
1.14% | 2 M€ | -1.17% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 483.7 | +1.43% | 362 729 |
24-05-06 | 476.9 | -0.78% | 298,173 |
24-05-03 | 480.6 | +1.00% | 547,954 |
24-05-02 | 475.8 | +1.66% | 518,332 |
24-05-01 | 468 | -5.02% | 1,018,227 |
Delayed Quote Nasdaq, May 07, 2024 at 12:09 pm EDT
More quotesEPS Revisions
- Stock Market
- Equities
- IDXX Stock